Feature|Videos|January 2, 2025
Final Thoughts
The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.
Advertisement
Episodes in this series
The panelists provide their closing thoughts on CAR T-cell therapies and what they look forward to as these therapies become popular beyond cancer, extending to autoimmune diseases as well. There is hope to remove manufacturing bottleneck so patient demand and access can improve.
Advertisement
Related to this article
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
The Most Important Lessons Learned from Building CGT Supply Chains: LogiPharma 2026
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
Viatris Acquires Pacira BioSciences for $1.65 Billion
5